LXR 1035
Latest Information Update: 03 May 2000
At a glance
- Originator LXR Biotechnology
- Class Antineoplastics; Lysophospholipids
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Stroke
Most Recent Events
- 03 May 2000 Discontinued-Preclinical for Myocardial infarction in USA (Unknown route)
- 03 May 2000 Discontinued-Preclinical for Stroke in USA (Unknown route)
- 03 Dec 1998 New profile